1. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman Tata Laksana Atrial Fibrilasi. 2014. https://inahrs.or.id/web_guidelines/download/F_5cecb06635e24.pdf
2. Killu AM, Granger CB, Gersh BJ. Risk stratification for stroke in atrial fibrillation: a critique. Eur Heart J 2019;40:1294-1302.
3. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, Sharan L, Allen LaPointe NM, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al- Khatib SM, Sanders GD. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118:2171-2187.
4. Lane DA, Lip GYH. Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. European Heart Journal Supplements, 2020. 22: O14–O27. https://doi.org/10.1093/eurheartj/suaa178
5. Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Lip GYH, Marin F. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-Stroke and CHA2DS2-VASc scores. J Am Heart Assoc 2017;6: pii: JAHA.117.006490. doi: 10.1161/JAHA.117.006490.
6. Jung H, Sung JH, Yang PS, Jang E, Yu HT, Kim TH, Pak HN, Lee MH, Joung B, . Lip GYH. Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2018;72:2409-2411.
7. Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest 2019;155:354-363.
8. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, Yu HT, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol 2018;72:1233-1245.
9. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European heart journal 2020 00.1-125.
10. Fangel MV, Nielsen PB, Larsen TB, Christensen B, Overvad TF, Lip GYH, Goldhaber SZ, Jensen MB. Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. Int J Cardiol 2018;268:137-142.
11. Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, . Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-1547.
12. Oladiran O, Nwosu I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. J Community Hosp Intern Med Perspect. 2019;9(2):113-120. Published 2019 Apr 12. doi:10.1080/20009666.2019.1593781
13. Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, Botker HE, Lip GYH, Maeng M. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart Registry. Thromb Haemost 2018;118:2162-2170.
14. Nielsen PB, Skjoth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?Circulation 2018;137:832-840.
15. Wu VC, Wu M, Aboyans V, Chang SH, Chen SW, Chen MC, Wang CL, Hsieh IC, Chu PH, Lin YS. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart 2020;106:534-540.
16. Tomasdottir M, Friberg L, Hijazi Z, Lindback J, Oldgren J. Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation. Clin Cardiol 2019;42:1003-1009.
17. Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Circulation, 2012. 126:860–865
18. Shin SY, Han SJ, Kim JS, Im SI, Shim J, Ahn J, Lee EM, Park YM, Kim JH, Lip GYH, Lim HE. Identification of markers associated with development of stroke in ‘clinically low-risk’ atrial fibrillation patients. J Am Heart Assoc 2019;8:e012697.
19. Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, Cui Y. Accuracy of HAS- BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta-analysis. J Thromb Haemost 2020;18:791-801
20. Chao TF, Liao JN, Tuan TC, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, Chen TJ, Lip GYH, Chen SA. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients. Thromb Haemost 2019;119:1162-1170.